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Abstract: Although bone graft is still considered as the gold standard method, bone tissue engineering
offers promising alternatives designed to mimic the extracellular matrix (ECM) and to guide
bone regeneration process. In this attempt, due to their similarity to the ECM and their low
toxicity/immunogenicity properties, growing attention is paid to natural polymers. In particular,
considering the early critical role of fracture hematoma for bone healing, fibrin, which constitutes
blood clot, is a candidate of choice. Indeed, in addition to its physiological roles in bone healing
cascade, fibrin biochemical characteristics make it suitable to be used as a multipurpose platform for
bioactive agents’ delivery. Thus, taking advantage of these key assets, researchers and clinicians have
the opportunity to develop composite systems that might further improve bone tissue reconstruction,
and more generally prevent/treat skeletal disorders.
Keywords: fibrin; natural polymers; biomaterials; delivery systems; bone regeneration
1. Introduction
Bone is a dynamic tissue resulting from a permanent remodeling process under the control of
bone-forming cells (i.e., osteoblasts) and bone-resorbing cells (i.e., osteoclasts). Thanks to this property,
the healing process can restore both biological and mechanical functions of bone in case of a non-critical
size defect [1]. However, in addition to size-related issues (critical defects which cannot be filled
with bone autograft), bone repair can be disturbed for reasons linked to age, individual behavior
(i.e., smoking, inactivity) and diseases (i.e., bone infections, tumors, osteoporosis). This prompted
the development of bone substitutes, available in large quantities and suitable for use in harsh
bone repair conditions. Thanks to a better understanding of molecular and cellular mechanisms
underlying bone regeneration, sophisticated biomaterials adapted for bone tissue engineering have
been developed [2,3]. In line with the growing development of bio-inspired materials, natural polymers
have attracted much attention, due to their similarity to the extracellular matrix (ECM), as well as
low toxicity/immunogenicity properties. Among them, a special attention has been given to fibrin,
and this review aims at providing the reader with a set of characteristics explaining the relevance of
fibrin choice for bone substitutes designing.
2. Fibrin Clot Action within Bone Healing Process
As depicted in Figure 1, fibrin constitutes the blood clot, the basic structure of fracture hematoma,
and it provides a temporary matrix for wounded tissue until complete remodeling. Fibrin also promotes
angiogenesis and osteogenic differentiation, hence favoring bone regeneration [4,5].
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Figure 1. Fibrin clot-induced physiological bone healing cascade [4].
In addition to that, fibrin displays particular features which offer the prospect of using it
as a versatile platform for the delivery of various agents favoring bone reconstruction in critical
situations. Thus, fibrin can be considered as a promising candidate capable to play a key dual role:
(i) enable physiological bone repair for critical defects; (ii) deliver bio-active compounds in particularly
adverse conditions.
After reminding fibrin physical and biological properties, this review will describe strategies to
tailor/tune and regulate the release profile of entrapped therapeutic compounds. Lastly, the broad
range of fibrin-based strategies will be illustrated by various examples related to the local delivery of
drugs, growth factors, genes and miRNAs.
3. Fibrin Physiological Properties
3.1. Composition, Structure, and Mechanical Properties
Fibrinogen is an elongated protein, 45 nm in length, which is made up of globular domains at each
end connected by alpha-helical coiled-coils to a globular region in the middle. Circulating fibrinogen
is cleaved by the action of the serine protease thrombin, resulting in the formation of an insoluble
three-dimensional network capable to entrap molecules and cells [6]. At sites of wound healing
and angiogenesis, transglutaminase factor XIII (F XIIIa) activation leads to the deposition and the
stabilization of fibrin clots. Once stabilized, these fibrin clots serve as a temporary matrix that
provides solid supports for invading fibroblasts and endothelial cells, before undergoing an enzymatic
degradation concomitant to the regeneration of damaged tissues [7].
Fibrin network formation must be tightly controlled as it influences the clot properties.
Indeed, various parameters influence the fibrin mesh thickness, porosity and permeability. In that
respect, thrombin, fibrinogen, H+ and Ca2+ concentrations, temperature, as well as the presence of
hyaluronic acid and plasma proteins, deeply affect the network microstructure [6,8,9]. For example,
high thrombin concentrations favor the formation of clot with thin fibers and small pores, whereas lower
concentrations tend to create clot with thick fibers and large pores [10]. The fibrinogen concentration
also regulates clot properties. Under physiological conditions (fibrinogen at a concentration of
2.5 g/L), plasma will rapidly clot to form a mechanically stable structure, with large spaces between
protofibrils, and much larger spaces between fibers. In this structure, fibrin represents only 0.25% of the
volume while 99.75% of the clot is made of fluid occupying the space between protein polymers [11].
Considering the small amount of material involved, fibrin networks display remarkable properties.
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Fibrin clot mechanical properties are extremely important for numerous clinical phenomena
including hemostasis, fibrinolysis, thrombus deformation in the blood flow and embolization.
Consequently, based on theoretical and experimental data, and in order to investigate the behavior of
fibrin networks upon mechanical deformations (shear deformation, strain stiffening etc.), a number of
models have been developed [12–15]. Among them, one is based on the viscoelastic properties of fibrin.
It demonstrates that its mechanical response depends on the duration and the rate of loading [16,17].
As deeply described by Weisel et al. [11], stress seems directly proportional to strain at low strains
whereas fibrin stiffness increases until 20-fold at larger strains. The authors suggest that fibrin network
expresses irreversible deformation but surprisingly, it can completely recover its stiffness after removing
the stress. Furthermore, fibrin has been shown to display a nonlinear mechanical response to external
compression [14]. Kim et al. define the three following distinct regimes (i) a linear viscoelastic response
to compression resulting in fibers become straight; (ii) a stress plateau where fibers buckle and collapse,
and (iii) a network densification characterized by a stress-strain nonlinear response and dominated by
bending of fibers after inter-fiber contact. Lastly, fibrin deformation occurs non-homogeneously along
the matrix [18]. To sum up, all these properties influence clot responses to forces such as stretching,
bending or buckling [17].
3.2. Biological Properties
In addition to these mechanical characteristics, fibrin displays at least two major biological
properties. First of all, it participates to hemostasis in wound healing. In addition, the blood clot
specifically interacts with numerous ECM proteins and growth factors such as fibronectin, vitronectin,
fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin-like growth factor-1
(IGF-1), and enzymes including plasminogen or tissue plasminogen activator [6]. By consequence,
fibrin provides also many cell types with a provisional matrix which supports tissue remodeling
and healing.
Within the specific context of bone repair, fibrin exerts a key role at the beginning of the process.
As mentioned above, an initial inflammatory response is required and produces chemotactic factors
which attract cells involved in tissue reconstruction. Figure 2 below illustrates how fibrin participates to
this critical step. Indeed, fibrin degradation products directly act on endothelial cells forming vascular
walls. Through a mechanism involving VLDL receptor and VE-cadherin junction proteins, leukocytes
transmigration occurred from surrounding vessels towards injured sites where they contribute to the
inflammatory response onset [19,20].
As illustrated above and under physiological conditions, the blood clot is not a permanent
structure. Fibrinogenesis and blood coagulation are counteracted by the fibrinolytic system in order to
preserve the hemostatic balance [21]. Regulating this balance is crucial to drive tissue formation and
neovascularization while allowing a progressive degradation of fibrin clot. When fibrin degradation
occurs too fast, which is observed for example at low concentration of fibrinogen (e.g., 9 mg/mL)
and thrombin (50 U/mL), osteogenic cells are not able to differentiate and produce their own matrix
to fill the defect site [22]. These negative effects can be reversed by increasing the content of fibrin
constituents. However, it is worth noting that fibrinogen and thrombin must be kept at physiological
concentrations, which provide a slow gelation time essential to protect entrapped cells from osmotic
shock and mechanical stress, and to preserve their differentiation potential.
A large set of data further support the notion that fibrin clot characteristics and its interactions
with cells are tightly linked. For example, the formation of dense hydrogels by increasing fibrinogen
concentration results in an inhibition of cells migration and proliferation [23,24], while it increases their
osteogenic differentiation, probably in response to the high concentration of growth factors trapped
inside the material [25]. The fibrinogen concentration also influences cells morphology. At high
fibrinogen concentration (50 mg/mL), cells are rounded whereas they appear elongated and spindle-like
at low fibrinogen concentration (5 mg/mL) [26]. Moreover, sodium chloride supplementation during gel
Pharmaceutics 2019, 11, 556 4 of 15
fabrication increases the ionic strength, and contributes to maintaining the viability and the osteogenic
potential of entrapped cells [27].
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Regarding in vitro cell culture, different surface treatments have been investigated. In this
way, precoating cell culture plates with 10 mg/mL fibrinogen promotes mesenchymal stem cells
(MSC) adhesion, proliferation and differentiation [28]. When compared to cells cultured directly on
tissue culture plastic, MSC preculture during 7 days on a fibrin matrix before re-seeding them onto
tissue culture plastic enhances their proliferation and their osteogenic properties [29]. Oh et al.
cultured MC3T3-E1 pre-osteoblasts on fibrin matrices prepared with various concentrations of
thrombin, and they reported that thrombin promotes fibrin-enhanced osteoblast differentiation in a
dose-dependent manner [30]. Furthermore, as regards various cells including fibroblasts, modulating
the plasma-derived fibrin concentration influences cellular characteristics including proliferation rate,
migration, ECM production and soluble factors secretion [31].
4. Preparing Fibrin for Bone Repair
Fibrin-derived products can be industrially manufactured using large plasma pools and
fractionation/precipitation steps, which include cryoprecipitation and ethanol fractionation [32–34].
These products contain concentrated fibrinogen (>80 g/L) and purified thrombin (500–1000 UI/mL)
obtained from the activation of prothrombin [35]. This manufacturing process leads also to the
purification of other plasma proteins, and growth factors concentration can be modified according to
the method used. Calcium chloride is usually added to accelerate fibrin polymerization. The fibrinogen
and thrombin components are mixed extemporaneously to form, within seconds, a fibrin clot that
adheres to tissues, mimicking the last step of the coagulation cascade. If it is necessary to slow down
fibrinolysis, formulations include antifibrinolytic agents, such as tranexamic acid, or low concentration
of thrombin (<10 IU/mL). As largely described in the literature, different fibrin glues with diverse
structures and mechanical/stiffness properties are commercially available [36]. Finally, regarding
clinical needs/outcomes, various applicators including sprays, double-syringes and endoscopic devices
are also on the market.
Fibrinogen-enriched products can also be prepared from single donations, mainly by using
cryoprecipitation. Briefly, cryoprecipitate isolated by centrifugation is suspended at room temperature
with residual cryo-poor plasma and used fresh or after freezing/thawing. It is considered that 200 mL
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of plasma provide approximately 15 mL of cryoprecipitate. The thrombin stability can be enhanced by
adding ethanol (10–15%) [37].
The selection of appropriate fibrin glue is mainly based on criteria such as ease of preparation,
safety, reproducibility and cost. Although single-donor fibrin is cheap and safe as compared to
commercial fibrin, it lacks satisfactory reproducibility. However, it can be prepared easily from
platelet-rich plasma, which constitutes a concentrated source of growth factors supporting bone
regeneration. As a matter of fact, platelet-rich fibrin mixed with inorganic bovine bone particles
(Bio-Oss®) significantly enhances bone augmentation in the maxillary sinus of a canine model [38].
These characteristics are summarized in Figure 3.
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5. Fibrin Handling for Bioactive Compounds Delivery
5.1. Tuning Fibrin Intrinsic Characteristics
Bioactive compounds including growth factors, cytokines, drugs, and nucleic acids can be easily
entrapped in the fibrin matrix by mixing them with fibrinog n or thrombin. In general, fibrin m trix
rem ins porous regardless he conditio s and/or thrombi and fibrinogen ratios. However, increasing
fibrinogen and/or thrombin concentrations de sifies the structure of a fibrin gel and reduces its
degr dation rate, thus slowing down the diffusion of loa d molecul s (e.g., FGF) [39].
In addition, the release profile of active c mpoun s is affected by their physicochemical properties
including partition coefficient, size and functional groups. For example, hydrop ilic molecules readily
leach out (e.g., erythromycin, mit my in C, fluorouracil etc.), while hydrophobic olecules, or t ose
which di play a strong chemical affinity for the matrix components, re released more gradually
(e.g., str pt mycin, sulfamethoxazole-trimet oprim, cefazolin, enocit bine etc.) [40–43]. Thus, some
compounds need to be modified chemically t bec me more hydrophobic, resulting in a prolonged
retention within the matrix. Conversely, a proteolytic degradation ay be required to speed up the
diffusi n process.
Lastly, fibrin matrix proteolysis through the action of thrombin or plasmin induces the release
of entrapped compounds. In rder to estrict this breakdown of the matrix, the co-entrapm nt of
proteolysis inhibitors (aprotinin, matrix m talloproteinases inhibit rs such as galardin) was investigated.
Ahmed et al. identified in their model (i.e., chondroprogenitor clonal cell line) the enzymes responsible
for fibrin gel breakdown [44]. It appeared that etal oproteinases (MMP-2, MMP-3, MMP-9) wer
secreted concomitantly with fibrin hydrogels breakdown. They also noted high plasmin activity in
the conditioned media du ing hydrogel breakdown. Then, they demonstrated that aprotini an
galardin, in combination or separately, prev nted fibrin hydrogels degradation. Figure 4 summariz s
the modifications which ca be made on fibrin matrix to regulate the release of entrapped agents.
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5.2. Modifying Fibrin and/or Active Agents for Efficient Combination and Delivery
In some instances, fibrin exhibits innate affinity for therapeutics and growth factors [45–48] but
in other cases, the covalent attachment of these compounds to fibrin is considered. This generally
requires chemical modifications with reactive functional groups (thiols, azides) allowing a stable
association [49]. Then, reduction/hydrolysis reactions or enzymatic cleavage mediate the release of
active molecules. It was shown that this approach prolongs the delivery phase of growth factors for
example [50].
As another illustration, covalently binding of BMP and RGD sequences to fibrin allows interactions
with bone marrow stromal cells through integrin surface receptors that triggered downstream signaling
pathways [51]. More sophisticated constructions have been tested. Starting from BMP-2, Schmoekel et al.
propose a tripartite fusion protein denoted as TG-pl-BMP-2 [52]. Under the control of the blood
transglutaminase factor XIIIa, the N-terminal transglutaminase substrate domain (TG) provides a
covalent attachment to fibrin during coagulation. In addition, upon the action of cell-activated plasmin,
the central plasmin substrate domain (pl) gives a cleavage site for the local release of the attached
growth factor from the fibrin matrix. Lastly, the C-terminal human BMP-2 domain displays an
osteogenic activity.
As an alternative to active molecules derivatization, fibrin functionalization can also be achieved.
For example, to facilitate BMP interaction with a fibrin matrix, Yang et al. grafted heparin onto fibrin,
this leading to electrostatic interactions between the negative charges of heparin sulfate groups, and the
positive charges of BMPs amino acid residues [53]. Interestingly, heparin presence slowed down fibrin
degradation, and consequently the release of loaded BMPs. Similar observations were made with
FGF [39].
Despite positive effects reported in literature, there are several drawbacks to fibrin or growth
factors/proteins functionalization. First of all, it requires specific skills, and it is time consuming and
expensive. Furthermore, proteins functionality can be altered by these modifications. Indeed, covalent
binding can mask active sites, thus affecting their bioactivity. As an alternative, non-modified
compounds can be internalized into particles, to slow down their release. Wang et al. developed
a sophisticated system which could serve to deliver low-molecular weight hydrophilic drugs [54].
They used an antithrombosis drug (i.e., Tirofiban®) as a drug model. Drug-loaded liposomes were
first encapsulated in a fibrin gel, and then combined to chitosan. To document/characterize the in vitro
drug release profile, different parameters were studied including the surface charge of liposomes,
the pore size of chitosan structure, and the crosslinking degree of fibrin gels. All these experimental
conditions offered different prolonged releases without altering the composite bioactivity. All these
modifications are summarized in Figure 4.
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6. Active Agents Used in Fibrin-Based Delivery Strategies
6.1. Active Agents for Bone Infections
Postoperative infections associated with the implantation or the revision of a bone medical device
generates undesirable morbidity [55]. In its most extreme occurrences, osteomyelitis, either acute
or chronic, can compromise the vital prognosis of the patient. Redl et al. were among the first to
investigate fibrin as a carrier for antibiotics [56]. They observed that approximately 85% of the antibiotic
was released within 72 h, and that gentamycin for example reduced clot strength by affecting fibrinogen
chain-crosslinking. Greco et al. observed similar results in vitro [40]. Tredwell et al. reported then that
erythromycin was released slowly over the first 2 hours but then degraded rapidly, whereas cefazolin
appeared more stable and was evenly liberated during the first day [41]. Interestingly, release
profiles correlated with molecules hydrophobicity and for example, a poorly soluble antibiotic such as
tetracycline was retained longer in fibrin network [42].
Regarding in vivo experiments, antibiotics such as vancomycin and sisomicin (a gentamycin
analogue), have been associated with fibrin glue and implanted in rats [57,58]. Pharmacokinetic studies
revealed a better distribution of drugs in the tissue around the implantation site when compared with
intravenous injections. In a model of methicillin-resistant Staphylococcus aureus infection, Ozaki et al.
reported that fibrin glue provided a sustained release of vancomycin, which was sufficient to prevent
the development of severe infections observed in the control group [59]. Interestingly, in the absence of
any systemic drug administration, topical administration of antibiotic via their fibrin glue was effective
against localized MRSA graft infection. Thus, topical administration of antibiotics may help to treat
difficult graft infections and to reduce the use of the systemic route.
Antibiotic resistance is a global health issue which jeopardizes the effectiveness of treatments for
a multitude of infections. A recent report published by the World Health Organization points out
that the current clinical pipeline is insufficient to tackle the challenge of antimicrobial resistance [60].
Therefore, more innovative long-term strategies are expected, with a view to eliminating pathogens
resistance. With this in mind, the use of bacteriophages could be a helpful approach. Bacteriophages
can be defined as viruses that specifically infect bacteria. Indeed, bacteriophages are good candidates
for antibacterial therapy as they are (i) non-toxic, (ii) highly specific, (iii) able to replicate themselves
as long as host bacteria are present, and finally (iv) some of them are able to penetrate and disrupt
biofilms, usually characterized by their high resistance to host immune defenses and to antibiotics
penetration [61,62]. Considering this powerful tool, Rubalskii et al. investigated the potential of fibrin
glue to incorporate and release bacteriophage in an effective manner [63]. Their data showed that the
high titers of bacteriophages released for 11 days were effective in killing Pseudomonas aeruginosa.
6.2. Active Agents for Pain Relief and Cancer Treatment
Postoperative pain after bone reconstruction is another serious complication that can jeopardize
surgery global success [64]. As a matter of fact, pain significantly reduces patients’ mobility, delays their
functional recovery, extends their hospital stay, and decreases their quality of life and autonomy. In this
context, different approaches have been explored to address these issues [65–67] and for example,
fibrin glue loaded with local anesthetics (lidocaine) was shown to reduce patients’ pain intensity after
surgery [67].
In relation with pain but also with structural integrity issues, bone tissue is one of the most
favored sites for metastasis of solid tumors (especially for prostate, breast, lung and kidney cancers),
and these lesions are preferentially localized in spine and pelvic bone [68]. For example, up to 70% of all
patients diagnosed with a breast cancer will develop bone metastases. These lesions ultimately cause
dramatic tissue defects that compromise bone structural integrity. This results in severe bone pain and
instability, fractures, spinal cord compressions, hypercalcemia and bone marrow aplasia. Thus, among
therapeutic approaches, the local release of chemotherapeutic drugs from fibrin gel was investigated.
The comparative analysis of various chemotherapeutic drugs release profiles revealed a short release
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period [43]. Thus, a burst release of doxorubicin from a fibrin gel was observed while sodium alginate
addition tended to extend release duration over several days [69]. In the same way as antibiotics,
chemotherapeutic drugs release rate correlates with molecules hydrophobicity, suggesting that the
release of lipophilic drugs may require matrix degradation, whereas water-soluble agents readily
diffuse out.
6.3. Growth Factors and Cytokines
As largely described, growth factors are strongly involved in the process of bone regeneration
as recapitulated in Table 1 [70–83]. They initiate the healing process by providing at the injury site
signals that are essential for the recruitment of inflammatory and progenitors cells. Among these
growth factors, bone matrix proteins (BMPs), including BMP-2 and 7, received special attention due to
their potent osteoinductive properties. In fact, they stimulate (i) the migration of mesenchymal stem
cells to bone-forming sites, (ii) their differentiation into an osteoblastic lineage, and (iii) bone tissue
regeneration. However, the adjustment of BMPs local concentration for a sufficient period of time
remains a challenge. Indeed, a short burst of BMPs not only causes deleterious effects on tissue but also
requires a more frequent administration, which is costly. To address these problems, the fibrin matrix
was tested to deliver BMPs and for example, BMP-2 was mixed with fibrinogen and thrombin [74] and
then injected into a rat femoral defect. When compared with a collagen sponge, and despite a seven-fold
lower content in growth factor, the BMP-2-loaded fibrin matrix displayed a superior osteogenic capacity.
Interestingly, in a rat calvarial defect model, the combination of BMP-2-loaded fibrin with calcium
phosphate particles improved fibrin composite action on bone repair [75]. In an effort to limit BMPs
diffusion toward undesired sites, Patel et al. encapsulated BMP-2-loaded collagen sponges in fibrin
glue. Unfortunately, BMP-2 still could diffuse through fibrin pores, probably because of its small size
and its low affinity for fibrin [76]. By contrast, in a rabbit spinal fusion model, conjugating heparin
to fibrin delayed the release of BMP-2, and resulted in biological results similar to those obtained
with autograft, which is the gold standard for bone reconstruction [77]. Lastly, it was shown that the
co-delivery of BMP-2 and platelet-derived growth factor (PDGF) enhanced vascularization and bone
formation in mouse calvarial defects [78].
Table 1. Main functions of growth factors used in bone tissue engineering [70–83].
Growth Factor Functions for Bone Regeneration
BMP
(Bone matrix protein)
Recruiting MSCs to the injury site
Triggering osteogenic differentiation of osteoprogenitors
FGF
(Fibroblast growth factor)
Stimulating proliferation of endothelial cells and osteoblasts
Promoting angiogenesis from preexisting vasculature
Regulating MSC, endothelial cells, fibroblasts and osteoblasts
PDGF
(Platelet-derived growth factor)
Promoting chemotaxis of MSC, macrophages, neutrophils, fibroblasts and osteoblasts
Modulating collagenase synthesis and collagen secretion
VEGF
(Vascular endothelial growth
factor)
Stimulating proliferation and migration of endothelial cells to regulate angiogenesis during bone
formation
Promoting recruitment and survival of bone forming cells
TGF-β
(Transforming growth factor β)
Stimulating proliferation of MSC, endothelial cells, fibroblasts and osteoblasts
Inhibiting macrophage and lymphocyte proliferation
Regulating collagenase synthesis and collagen secretion
Vascularization plays a critical role in bone fractures healing. Vessels not only provide oxygen
and a nutritional support for newly formed tissues, but they also constitute a network allowing the
circulation of inflammatory cells, progenitors and growth factors such as VEGF. VEGF is considered as
the most important angiogenic factor involved in bone formation [70]. By stimulating the proliferation
and migration of endothelial cells, VEGF promotes blood vessels formation, and thus the recruitment
and the survival of bone forming cells. Burkhardt et al. have reported the physiological importance of
blood clots to create a pro-angiogenic environment which favored healing response [79].
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Numerous delivery systems, for VEGF alone or combined with other growth factors, have been
developed. For example, in a canine model of femoral neck fracture, bone delivery of VEGF incorporated
into fibrin-suspended PLGA microspheres induced significant osteogenic and angiogenic effects [80].
Regarding the release kinetic profiles, a sequential release of two growth factors was achieved using a
VEGF-loaded gelatin hydrogel surrounding a poly(propylene) core, which included BMP-2-loaded
PLGA (polylactic-co-glycolic acid) microspheres [81]. Indeed, in a rat model, an initial burst release of
VEGF was observed during the first three days, whereas BMP-2 displayed a sustained release over
the full 56-day implantation period. Similarly, using a dual delivery system of BMP-2 and VEGF,
Subbiah et al. reported a beneficial effect on both angiogenesis and osteogenesis [82].
6.4. Genes
Severe postoperative complications, including osteolysis, overgrowth and pseudarthrosis have
been observed following the administration of highly concentrated BMP-2 protein [84]. With this
respect, the use of coding DNAs under the control of suitable promoters, transfected or transduced in
relevant cells, appeared as an alternative way to supply growth factors. For that purpose, incorporating
viral and non-viral vectors into fibrin glue was investigated to deliver genes.
Considering that transcriptional activity declines rapidly, a sustained release is required to
achieve long-term effects. Ionic interaction of DNA with the matrix may favor retention of the
vector [85]. A preliminary study in a rabbit ear ulcer model investigated the ability of fibrin to
deliver a low single dose of viral vector (i.e., adenovirus encoding beta-galactosidase) to a wound
site, without compromising transfection efficiency [86]. Although transgene expression was enhanced
in the fibrin containing adenovirus group at seven days, no difference was measured at 14 days
when compared to the control group, and the presence of the virus did not cause any unfavorable
inflammatory response. Des Rieux et al. reported that non-viral vectors could be efficiently entrapped
within a fibrin hydrogel, and that after one day in solution, more than 70% of the entrapped DNA was
still retained within the gel, with a sustained release observed for at least 19 days [87]. Recently, Bara et al.
combined a doxycycline-inducible adenoviral vector with mesenchymal stem cells, fibrin and calcium
phosphate granules [88]. Although only low levels of BMP-2 protein secretion were measured in vitro
(ng/mL), in vivo implantation into a rat bone critical defect for 12 weeks revealed an improvement of
bone regeneration. By suggesting that low levels of growth factors could be effective for promoting an
appropriate tissue response, this result may validate the delivery gene method as a relevant alternative
approach to the use of peptides or proteins.
6.5. miRNAs/siRNA
Small interfering RNA (siRNA) is defined as a gene-silencing mechanism by which
post-transcriptional gene silencing can occur. Delivering a siRNA alone is very complicated because
of negative charges preventing its internalization through the cell membrane. Moreover, siRNA
molecules are susceptible to degradation. To circumvent these limits, various approaches including
viral and non-viral vector-mediated delivery have been explored [89]. For example, the noggin siRNA,
an antagonist to BMP-2, was packaged into a non-viral vector and then embedded into a fibrin gel [90].
In vitro studies showed, after a 48 h treatment, a significant intracellular uptake of siRNA in over 98%
of osteoblasts. These low doses of noggin siRNA were sufficient to significantly reduce noggin mRNA
levels in exposed cells, without altering their viability.
7. Conclusions and Perspectives
Despite the benefits that minimally invasive osteosynthesis and surgery have brought to bone
repair, there are still many circumstances where achieving bone healing remains challenging. In this
context of bone reconstructive surgery, fibrin has shown a high potential. This was not only as a source
of growth factors with osteoconductive properties, but also as a delivery system for active biological
compounds that could further improve bone tissue regeneration or more generally prevent/treat
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skeletal disorders. However, clinical effectiveness is still controversial, depending on the variability
of fibrin preparation protocols used, and the limited number of patients included in the trial [91,92].
For example, no positive effects of fibrin have been notified in patients after total knee replacement
surgery [93], whereas fibrin provided beneficial effects in improving alveolar preservation on extraction
sockets and around dental implants [94]. Hence, further well-designed clinical trials are expected to
conclude on the effectiveness of fibrin.
Nowadays, innovative approaches are explored to optimize fibrin properties in terms of
mechanical and biological responses. Most of studies are focused on improving its mechanical
strength through the addition of other polymers or biomaterials, including calcium phosphates (CaP).
Interestingly, CaP-based biomaterials not only provide sufficient mechanical properties, but also a
favorable support for cell attraction, proliferation and activity [2,3,95]. Indeed, as compared to fibrin
alone, cell proliferation strongly increased in the presence of CaP-based materials/fibrin composites [96].
In addition, cells are necessary to support bone tissue healing/regeneration, and thus might confer
to fibrin supplemental osteogenic properties. In this attempt, fibrin can serve as delivery system for
different cell types including fibroblasts [97], osteoblasts [98], dental stem cells [99] and mesenchymal
stem cells isolated from various sources [23,100]. Recently, embryonic and induced pluripotent stem
cell-derived progenitor cells have been uniformly mixed within fibrin [101]. Interestingly, high cell
seeding densities have been reached successfully, this resulting in good viability, proliferation and
differentiation properties [22,25]. However, further experiments are required to study the impact of
fibrin intrinsic properties (i.e., composition/structure/stiffness etc.) on cell behavior. Understanding and
controlling these interactions might encourage the use of fibrin as a carrier rather than systemic
injections for cells administration.
At the present time, a growing interest focuses on fibrin-based nanostructures to provide a
suitable natural matrix environment supporting bone regeneration. These nanoscaffolds are explored
in tissue regenerative medicine to deliver drugs, active biomolecules, cells and genes. For example,
Praveen et al. prepared fibrin nanoconstructs (FNCs) including nanotubes and nanoparticles, through a
modified water-in-oil emulsification-diffusion route, and without the use of any surfactants [102].
Surprisingly, these constructs displayed a high resistance to aggregation, and excellent temperature
stability up to 200 ◦C. Tacrolimus, an immunosuppressive drug, was encapsulated into these fibrin
nanostructures. A sustained and complete drug release has been observed over a period of one
week. Further in vivo experiments are expected to prove the therapeutic efficiency of these constructs.
Nanofibrin has been also incorporated into a chitin-CaSO4 injectable gel to improve its rheological
behavior as well as its pro-angiogenic properties [103]. Indeed, rheological studies reported that the
composite gel including nanofibrin was a shear thinning gel, with an elastic modulus increased by
1.67-fold over the chitin control. In vitro studies performed on rabbit adipose-derived mesenchymal
stem cells (rASCs) demonstrated that nanofibrin addition tends to enhance rASCs activities. In another
study, the authors addressed the issue of vasculature stimulation through the design of a nanocomposite
injectable hydrogels [104]. These gels were based on chitin and poly (butylene succinate) (PBSu)
loaded with fibrin nanoparticles (FNPs) and magnesium-doped bioglass (MBG). FNPs were expected
to promote vascularization, whereas MBG might stimulate early osteogenesis. Authors demonstrated
that composites containing 2% FNPs and 5% MBG displayed good rheological properties, injectability,
temperature stability, biomineralization and protein adsorption without inducing cytotoxicity. They also
reported an enhancement of both pro-angiogenic and osteoinductive properties.
Considering bone repair, smart solutions including nanocomposites are emerging.
However, keeping in mind a potential strong impact on cell responses, and thus on bone tissue
full rehabilitation, these last generation biomaterials require further in-depth analysis.
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